1st Annual European Neuroscience Innovation Forum

Galimedix is a Phase 2 clinical-stage private company developing novel oral and topical neuroprotective therapies for serious brain and retinal diseases.

Lead program, GAL-101 (eye drops), is in a Phase 2 trial for the treatment of geographic atrophy (GA), a severe form of dry age-related macular degeneration (dAMD). An oral formulation of GAL-101 has successfully completed Phase 1 testing and shown to be safe, well tolerated, and effectively crosses the blood-brain barrier. Target engagement could be shown. Phase 2 trials in Alzheimer’s (oral) and glaucoma (eye drops) are planned. A next-generation compound, GAL-301, is in pre-clinical testing.
Galimedix is looking for crossover financing to progress GAL-101 to clinical proof of concept in Alzheimer´s disease and to advance its earlier-stage programs ahead of a planned US IPO.

Galimedix has signed a licensing and equity deal with Théa Open Innovation for co-development and commercial rights to GAL-101 in ophthalmology, excluding APAC and is pursuing additional regional partnerships.

Recent highlights include the successful completion of the first-in-human study of the oral version of GAL-101, data presented at CTAD, and the ongoing Phase 2 eDREAM trial in GA, with LPI anticipated this year.

Founded in 2003, Aprecia Pharmaceuticals is a pioneering force in additive manufacturing, dedicated to revolutionizing drug delivery through three-dimensional printing (3DP) technology. With over 20 years of innovation, Aprecia remains the first and only 3DP company in the world to achieve regulatory product approval, bringing groundbreaking products like Spiritam® to market. Boasting 126 granted patents and 52 pending, Aprecia’s commitment to innovation is unmatched. Aprecia is led by a team of seasoned pharmaceutical experts and continues to develop unique pharmaceutical products through global partnerships, leveraging technology originally developed at MIT. Our commitment to quality and regulatory compliance is reflected in our exemplary track record and partnership with the FDA through the product approval process and Emerging Technology Program (ETP).

Curlim is a late stage preclinical  biotech company developing an innovative encapsulation platform designed to improve the therapeutic efficacy of bioactive molecules. First applications target hereditary peripheral neuropathies and neurodegenerative diseases.

Lead indication is CMT1a, the most common hereditary neuropathy, causing lifelong progressive motor disorders beginning in childhood.

At present, there is no pharmacological treatment for nervous disorders known as peripheral neuropathies. Charcot-Marie-Tooth disease type 1A (CMT1A) is the most common hereditary peripheral neuropathy (HPN). Therapeutic strategies remain very limited and do not address the cause of the disease, but mainly its symptoms. This lack of pharmacological treatment is particularly dramatic in the case of hereditary peripheral neuropathies, as they are diffuse and often manifest very early in the patient's life and persist throughout their lifetime.

Our solution has been developed by LImoges labs (neuro and sciences) and consists of a Platform technology. The platform is a novel cationic beta-cyclodextrin crystalline-nanocrystal (B-CD/CNC) nanocarrier system for improved solubility, bioavailability, and cellular penetration of APIs.

Our compund CLM001 Targets Oxidative Stress, Heavily Implicated in Peripheral Neuropathies.

CLM001 obtained unprecedented and spectacular therapeutic effects demonstrated on 2 CMT1A animal models showing anti-inflammatory, antioxidant, and remyelinating effects, with no toxicity signals.

CLM001 shows a significant rescue in the nerve function. When treated for a total of 12 weeks, CLM001 significantly improved balance/speed and increased the nerve conductivity.

In parallel, Primary and secondary modes of action have been characterized.

From a regulatory point of view, Orphan Drug Designation has been granted both by EMA and by FDA.

CMC is finalized and next development stage will be the launch of pre-clinical toxicology study.

Elkedonia is a French biotech developing first-in-class neuroplastogenic therapeutics targeting treatment-resistant depression. Our novel precision medicine approach offers a non-hallucinogenic, non-addictive alternative to current treatments. Seed-funded (€11.25M), operating across France & Belgium.